Get the Stockscreener App
8.82
1.36%
-0.1212
Pre-market:
8.95
0.13
+1.47%
Cns Pharmaceuticals Inc stock is traded at $8.82, with a volume of 84,563.
It is down -1.36% in the last 24 hours and down -4.67% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$8.9412
Open:
$8.75
24h Volume:
84,563
Relative Volume:
0.63
Market Cap:
$48.17M
Revenue:
-
Net Income/Loss:
$-17.06M
P/E Ratio:
-0.1247
EPS:
-70.7173
Net Cash Flow:
$-14.18M
1W Performance:
-15.15%
1M Performance:
-4.67%
6M Performance:
-85.73%
1Y Performance:
-98.61%
1-Day Range:
$8.25
$9.62
1-Week Range:
$7.9128
$11.16
52-Week Range:
$7.9128
$744.00
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
8.82 | 4.73M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
Is CNS Pharmaceuticals Inc. a good long term investmentSkyrocketing returns - jammulinksnews.com
CNS Pharmaceuticals Announces Reverse Stock Split - TipRanks
What drives CNS Pharmaceuticals Inc. stock priceFree Wealth Management Insights - jammulinksnews.com
What analysts say about CNS Pharmaceuticals Inc. stockDynamic profit expansion - printweek.in
CNS Pharmaceuticals CEO Shares Brain Cancer Treatment Vision at Investor Conference | CNSP Stock News - Stock Titan
CNS Pharmaceuticals To Carry Out 1-for-12 Reverse Stock Split On July 22nd, 2025 - 富途牛牛
CNS Pharmaceuticals Inc. Stock Analysis and ForecastExponentially increasing returns - Autocar Professional
CNS Pharmaceuticals Implements 1-for-12 Reverse Stock Split to Consolidate Shares and Improve Market Position - AInvest
Published on: 2025-07-19 01:04:34 - jammulinksnews.com
CNS Pharmaceuticals (NASDAQ: CNSP) Announces 1-for-12 Reverse Stock Split Effective July 22 - Barchart.com
CNS Pharmaceuticals announces 1-for-12 reverse stock split - Investing.com
CNS Pharmaceuticals announces 1-for-12 reverse stock split By Investing.com - Investing.com UK
Brain Cancer Drug Developer CNS Pharmaceuticals Announces 1:12 Reverse Split to Maintain Nasdaq Listing - Stock Titan
How CNS Pharmaceuticals Inc. stock performs during market volatility3x Growth Potential - Newser
CNS Pharmaceuticals Posts Investor Presentation on Brain Cancer - TipRanks
CNSP SEC FilingsCNS Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
What makes CNS Pharmaceuticals Inc. stock price move sharplySmart Money Trade Setups - Newser
Why CNS Pharmaceuticals Inc. stock attracts strong analyst attentionSafe and Smart Investment Picks - Newser
Biohaven, Bexorg Partner to Accelerate CNS Drug Discovery Using Novel Whole-Brain Platform - Yahoo Finance
Jazz Looks To Block Avadel From Asking For Sleep Drug OK - Law360
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Lead Program In Virtual CEO Segment - Barchart.com
CNS Pharmaceuticals: TPI 287 Shows Potential in Treating CNS Tumors, CEO Discusses Recent Clinical Data at Virtual Investor CEO Connect Segment - AInvest
CNS Pharma CEO Shares Exclusive Insights on Novel Brain Cancer Treatment TPI 287 at Healthcare Leaders Meeting - Stock Titan
CNS Pharmaceuticals (NASDAQ:CNSP) Shares Down 2% – Here’s What Happened - Defense World
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights GBM Treatment Insights In KOL Segment Featuring Dr. Erin Dunbar - Barchart.com
CNS Pharmaceuticals Inc. Sheds Light on GBM Treatment Advances in KOL Segment with Dr. Erin Dunbar - citybuzz -
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Featuring Dr. Erin Dunbar Discussing Glioblastoma Multiforme and Lead Product Candidate TPI 287 - AInvest
Axsome Therapeutics’ SWOT analysis: stock’s potential in CNS market - Investing.com
Revolutionary Nasal Drug Delivery System Could Transform Treatment of Opioid Overdose and Epilepsy - Stock Titan
Citadel Advisors LLC Takes Position in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) - Defense World
Jane Street Group LLC Boosts Stake in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) - Defense World
Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development - Yahoo Finance
CNS Pharmaceuticals (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit - Barchart.com
CNS Pharmaceuticals Inc. to Showcase Glioblastoma Treatment Advancements at Brain Tumor Biotech Summit - citybuzz -
CNSP: Insights on TPI 287's Promise at Brain Tumor Summit | CNSP Stock News - GuruFocus
CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit | CNSP Stock News - GuruFocus
Brain Cancer Breakthrough: New Drug Achieves 12 Responses in Glioblastoma Patients, FDA Grants Special Status - Stock Titan
Factor Thisâ„¢ Energy Understood. All Factored In. - FinancialContent
CNS Pharmaceuticals (CNSP) Target Price Increased Amid Focus Shift to TPI-287 | CNSP Stock News - GuruFocus
Cortice Biosciences Transfers Orphan Drug Designations for TPI 287 in Brain Cancer and CNS Diseases - OncLive
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):